- Home
- BGT vs CLYM Comparison
BGT vs CLYM Comparison
Compare BGT & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGT
- CLYM
- Stock Information
- Founded
- BGT 2004
- CLYM 2018
- Country
- BGT United States
- CLYM United States
- Employees
- BGT N/A
- CLYM N/A
- Industry
- BGT Trusts Except Educational Religious and Charitable
- CLYM
- Sector
- BGT Finance
- CLYM
- Exchange
- BGT Nasdaq
- CLYM NYSE
- Market Cap
- BGT 294.6M
- CLYM 242.8M
- IPO Year
- BGT N/A
- CLYM 2021
- Fundamental
- Price
- BGT $13.03
- CLYM $3.01
- Analyst Decision
- BGT
- CLYM
- Analyst Count
- BGT 0
- CLYM 0
- Target Price
- BGT N/A
- CLYM N/A
- AVG Volume (30 Days)
- BGT 107.2K
- CLYM 338.5K
- Earning Date
- BGT 01-01-0001
- CLYM 11-12-2024
- Dividend Yield
- BGT 10.77%
- CLYM N/A
- EPS Growth
- BGT N/A
- CLYM N/A
- EPS
- BGT N/A
- CLYM N/A
- Revenue
- BGT N/A
- CLYM N/A
- Revenue This Year
- BGT N/A
- CLYM N/A
- Revenue Next Year
- BGT N/A
- CLYM N/A
- P/E Ratio
- BGT N/A
- CLYM N/A
- Revenue Growth
- BGT N/A
- CLYM N/A
- 52 Week Low
- BGT $10.89
- CLYM $2.35
- 52 Week High
- BGT $13.42
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- BGT 50.35
- CLYM N/A
- Support Level
- BGT $12.90
- CLYM N/A
- Resistance Level
- BGT $13.09
- CLYM N/A
- Average True Range (ATR)
- BGT 0.19
- CLYM 0.00
- MACD
- BGT -0.01
- CLYM 0.00
- Stochastic Oscillator
- BGT 30.95
- CLYM 0.00
About BGT BlackRock Floating Rate Income Trust
Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.